Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

CytomX Therapeutics (CTMX) EBIT (2016 - 2025)

CytomX Therapeutics' EBIT history spans 12 years, with the latest figure at -$9.2 million for Q4 2025.

  • For Q4 2025, EBIT fell 151.85% year-over-year to -$9.2 million; the TTM value through Dec 2025 reached -$3.6 million, down 114.4%, while the annual FY2025 figure was -$3.6 million, 114.39% down from the prior year.
  • EBIT reached -$9.2 million in Q4 2025 per CTMX's latest filing, up from -$15.8 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of $22.6 million in Q1 2025 to a low of -$34.9 million in Q4 2021.
  • Average EBIT over 5 years is -$10.1 million, with a median of -$8.8 million recorded in 2024.
  • Peak YoY movement for EBIT: soared 3017.33% in 2024, then tumbled 483.56% in 2025.
  • A 5-year view of EBIT shows it stood at -$34.9 million in 2021, then surged by 72.76% to -$9.5 million in 2022, then soared by 93.63% to -$606000.0 in 2023, then skyrocketed by 3017.33% to $17.7 million in 2024, then plummeted by 151.85% to -$9.2 million in 2025.
  • Per Business Quant, the three most recent readings for CTMX's EBIT are -$9.2 million (Q4 2025), -$15.8 million (Q3 2025), and -$1.3 million (Q2 2025).